Article Per Year (5 Year)
p-Index From 2021 - 2026
0.408
P-Index
This Author published in this journals
All Journal Journal of Applied Pharmaceutical Research
Jadi, Rajendra Kumar
Unknown Affiliation
Medicine & Pharmacology

Published : 2 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 2 Documents
Search

 1 
Formulation, development, and characterization of loratadine emulgel Sharaff, Chandana Setty; Renukuntla, Pranay; Peddapalli, Himabindu; Kuchukuntla, Mounika; Bakshi, Vasudha; Jadi, Rajendra Kumar
Journal of Applied Pharmaceutical Research Vol. 12 No. 2 (2024)
Publisher : Creative Pharma Assent

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.18231/j.joapr.2024.12.2.42.50

Abstract

Background: This study was to develop loratadine (LTD) emulgels to treat localized skin allergy. Method: Initially oil-in-water emulsion was prepared by 3 different types of surfactants & finally gelling agent carbopol 940 was incorporated into emulsion to produce emulgel (i.e., standard conventional method). Results: The developed formulations were characterized using various parameters including particle size (PS), zeta potential (ZP), polydispersity index (PDI), entrapment efficacy (EE), pH, extrusion efficacy, physical stability, in-vitro drug release studies, and scanning electron microscopy (SEM). PS, EE, PDI, ZP and In-vitro studies ranges between 186.25 ± 6.42 mm (LE-F4) to 395.24 ± 8.64 mm (LE-F1), 62.38 ± 0.36 % (LE-F2) to 76.48 ± 0.69 % (LE-F4), 0.276 ± 0.02 (LE-F4) to 0.652 ± 0.02 (LE-F1), 16.45 ± 2.13 mV (LE-F1) to 29.46 ± 2.78 mV (LE-F3) and 21.90 ± 0.3 % (LE-F1) to 68.30±0.9 % (LE-F4) respectively. Conclusion: Based on all physicochemical properties, LE-F4 formulation was considered to be optimized with minimum PS (186.25±6.42 nm), PDI (0.276±0.02), satisfactory positive surface charge (23.15 ± 1.89 mV) and maximum EE (76.48±0.69 %). FTIR studies were confirmed that there is no physical interaction between drug and excipients and SEM studies revealed that vesicle size was spherical with smooth texture. A significantly greater rate of drug release (i.e., 68.30 ± 0.90%) was seen in the LTD emulgels that were made with cationic surfactant (i.e., LE-F4) and found to be good spreadability and extrudability.
Insights of nose to brain delivery in treating Parkinson’s disease: A systematic review Pranay, Renukuntla; Tatikayala, Ravi Kumar; Damera, Sujatha; Pathakala, Naveen; Jadi, Rajendra Kumar
Journal of Applied Pharmaceutical Research Vol. 12 No. 6 (2024)
Publisher : Creative Pharma Assent

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.69857/joapr.v12i6.625

Abstract

Background: In Parkinson's disease (PD), a complicated neurodegenerative ailment, neurons in the substantia nigra that produce dopamine are lost, resulting in an insufficiency of the neurotransmitter that is essential for the regulation of voluntary and smooth muscular movements. This review focuses on the obstacle triggering the effectiveness of traditional PD treatments, which is the blood-brain barrier (BBB), which prevents some therapeutic medicines from reaching the brain. It encompasses the potential strategy of nose-to-brain administration by innovative approaches, including nanoparticles, liposomes, dendrimers, and cell-based carriers, directly delivering the drugs from nose to brain. Methods: The methodology involved examining the characteristics, advantages, applications, and challenges of various nanoparticles like SLNs, Nanoliposomes, Quantum dots, dendrimers, etc., through meticulous analysis of articles including from PubMed (5), ScienceDirect (5), Bentham Science (4) and Scopus databases (5). Conclusion: The review concludes by emphasizing the potential applications of nanoparticles in circumventing the problems encountered with traditional methods of drug administration in treating PD. This detailed study brings to light the applications and the challenges that need to be faced in utilizing nanoparticles for nose-to-brain delivery. Attention is directed towards the enlightenment of advanced carriers that target specific brain regions via the olfactory and trigeminal routes. The drug directly reaches the brain, bypassing BBB.
Co-Authors Bakshi, Vasudha Damera, Sujatha Kuchukuntla, Mounika Pathakala, Naveen Peddapalli, Himabindu Pranay, Renukuntla Renukuntla, Pranay Sharaff, Chandana Setty Tatikayala, Ravi Kumar